An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Arcus Biosciences Announces New Employment Inducement Grants
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Arcus Biosciences, Inc. (NYSE:RCUS) Announces Equity Awards for New Employees. The Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 21,200 shares of the Company’s common stock at an exercise price per share of $19.50, and restricted stock units to acquire a total of 10,600 shares of the Company’s common stock. These equity awards were granted pursuant to the Company’s 2020 Inducement Plan, approved by the Company’s Board of Directors in January 2020.
Positive
None.
Negative
None.
HAYWARD, Calif.--(BUSINESS WIRE)--
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 21,200 shares of the Company’s common stock at an exercise price per share of $19.50, which was the closing price on July 24, 2023, and restricted stock units to acquire a total of 10,600 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 A2a/A2b receptors) and HIF-2α. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
Investor Inquiries:
Pia Banerjee
Head of Investor Relations & Strategy
(617) 459-2006
pbanerjee@arcusbio.com
Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Source: Arcus Biosciences
FAQ
What is the latest announcement from Arcus Biosciences, Inc. (NYSE:RCUS)?
Arcus Biosciences, Inc. (NYSE:RCUS) announced the granting of equity awards to five new employees.
How many shares of the Company’s common stock were granted to the new employees?
The new employees were granted options to purchase a total of 21,200 shares and restricted stock units to acquire a total of 10,600 shares of the Company’s common stock.
Under which plan were the equity awards granted?
The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020.
